- Home
- INBX vs PROK Comparison
INBX vs PROK Comparison
Compare INBX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | PROK |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 316.0M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INBX | PROK |
|---|---|---|
| Price | $102.04 | $1.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $150.00 | $7.40 |
| AVG Volume (30 Days) | 306.3K | ★ 1.2M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 550.00 | ★ 1075.00 |
| 52 Week Low | $28.16 | $1.30 |
| 52 Week High | $155.29 | $3.48 |
Technical Indicators
Market Signals| Indicator | INBX | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 41.68 |
| Support Level | $96.60 | $1.56 |
| Resistance Level | $106.40 | $2.01 |
| Average True Range (ATR) | 6.82 | 0.12 |
| MACD | -1.90 | -0.04 |
| Stochastic Oscillator | 18.19 | 13.48 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.